Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    s1304
Show Display Options
Rank Status Study
1 Active, not recruiting S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
Conditions: Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Drug: Carfilzomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis

Study has passed its completion date and status has not been verified in more than two years.